Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Purple Biotech (PPBT) EPS (Basic) (2016 - 2025)

Purple Biotech has reported EPS (Basic) over the past 6 years, most recently at -$41.31 for Q4 2022.

  • Quarterly EPS (Basic) fell 14406.95% to -$41.31 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$41.0 through Dec 2022, down 8695.99% year-over-year, with the annual reading at $0.03 for FY2025, 99.39% down from the prior year.
  • EPS (Basic) was -$41.31 for Q4 2022 at Purple Biotech, down from $0.29 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $0.29 in Q4 2021 and troughed at -$41.31 in Q4 2022.
  • The 5-year median for EPS (Basic) is $0.02 (2018), against an average of -$8.16.
  • Year-over-year, EPS (Basic) soared 1409.16% in 2021 and then plummeted 14406.95% in 2022.
  • A 5-year view of EPS (Basic) shows it stood at $0.02 in 2018, then skyrocketed by 588.28% to $0.17 in 2019, then tumbled by 88.69% to $0.02 in 2020, then soared by 1409.16% to $0.29 in 2021, then tumbled by 14406.95% to -$41.31 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's EPS (Basic) are -$41.31 (Q4 2022), $0.29 (Q4 2021), and $0.02 (Q4 2020).